RxDoctor Payments Data

Yelena Drexler, MD

Nephrology · Miami, FLNPI 1225354186

Payments from drug & device makers

$184,744in general payments, 2019–2025

Across 79 payments — averaging $2338.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$90K
  • AstraZeneca$30K
  • Travere Therapeutics, Inc.$28K
  • Biogen$24K
  • Genentech USA, Inc.$7K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$4K
  • plus $2K from 4 others

What the payments were for

  • Consulting fees$37,31387%
  • Travel & lodging$3,5108%
  • Food & beverage$1,9565%
  • Education$700%

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$184,744 in reported general payments places this provider in the 90th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$61,308
Medicare patients
199
Services billed
440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan11$214,507
JardianceEmpagliflozin54$62,469
FarxigaDapagliflozin Propanediol41$40,823
OzempicSemaglutide24$28,462
Chlorthalidone59$1,324
Nebivolol Hcl11$991
Bumetanide12$476
Amlodipine Besylate42$331
Olmesartan Medoxomil24$277
Losartan Potassium46$225
Lisinopril16$111
Metoprolol Succinate18$95
Telmisartan12$87
Atorvastatin Calcium18$75
Furosemide11$56

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$29,889$40,82341 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 756 nephrology providers in Florida.

Other nephrology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →